2026 Pediatric Rheumatology Symposium

March 18-21, 2026. Minneapolis, MN.

View by Number View by Title View Sessions

Abstract Number: 062

Evaluating the Relationship Between an Electronic Transition Planning Tool and Transition Success in a Pediatric Rheumatology Clinic
Abstract Number: 063

Improving Pediatric Lupus Patient Education: Patient and Provider Needs Assessment
Abstract Number: 064

Recognizing Paradoxical Psoriasis in TNF-Inhibitor–Treated Pediatric Rheumatic Disease: A Saskatchewan Experience
Abstract Number: 065

Screening for Social Determinants of Health Identifies Differences Based on Insurance Types in a Single Pediatric Rheumatology Division
Abstract Number: 066

Incidence of Juvenile Idiopathic Arthritis in Chile: Estimates from a National Universal Access Program, 2010-2024
Abstract Number: 067

Standardizing Effective Education and Intervention for Chronic Non-Inflammatory Pain in Children with Juvenile Idiopathic Arthritis: A Quality Improvement Initiative
Abstract Number: 068

Identification of Challenges in the Quality of Referrals to a Pediatric Rheumatology Center: A Retrospective Chart Review
Abstract Number: 069

The Biologic Abatement and Capturing Kids’ Outcomes and Flare Frequency in Juvenile Spondyloarthritis trial: Baseline cohort characteristics and importance of stakeholder partner-informed knowledge translation and exchange
Abstract Number: 070

Empowering Voices: Inception of a Parent Led Anatomical Visual Pain Assessment Tool for Juvenile Arthritis
Abstract Number: 071

The Association Between Age at Diagnosis and Health-Related Quality of Life in Takayasu Arteritis
Abstract Number: 072

SOCS1 Haploinsufficiency: Functional Evidence Supporting an Expanded Clinical Phenotype
Abstract Number: 073

Interleukin-6 and Interleukin-12 Stimulation Increases Fibroblast Migration in Localized Scleroderma and Healthy Control Primary Fibroblasts
Abstract Number: 074

Tissue Protein Expression Profiling of Interferon Gamma and Frizzled-Wnt-related Signaling Show Increased Periadnexal and Perivascular Localization in Juvenile Localized Scleroderma Skin
Abstract Number: 075

Association of Anti-Cytokine Biologics and JAK inhibitors with Bronchoalveolar Fluid Cytokine Profiles in Patients with Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease (SJIA-LD)
Abstract Number: 076

Understanding Etiology (CLUE) Study: Whole Genome Sequencing of Childhood-onset Systemic Lupus Erythematosus

« Previous Page
1
…
3
4
5
6
7
…
10
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].